Health Care & Life Sciences » Biotechnology | Tikcro Technologies Ltd.

Tikcro Technologies Ltd. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
9,517.00
8,807.00
8,610.00
7,557.00
6,562.00
5,295
Total Accounts Receivable
-
-
-
27.00
9.00
9
Other Current Assets
14.00
25.00
123.00
12.00
12.00
43
Total Current Assets
9,531.00
8,832.00
8,733.00
7,596.00
6,583.00
5,347
Net Property, Plant & Equipment
-
88.00
67.00
136.00
125.00
100
Total Assets
9,531.00
8,920.00
8,800.00
7,732.00
6,708.00
5,447
Accounts Payable
63.00
-
-
-
-
Other Current Liabilities
65.00
184.00
226.00
237.00
309.00
Total Current Liabilities
128.00
184.00
226.00
237.00
309.00
Total Liabilities
128.00
184.00
226.00
237.00
309.00
Common Equity (Total)
9,403.00
8,736.00
8,574.00
7,495.00
6,399.00
Total Shareholders' Equity
9,403.00
8,736.00
8,574.00
7,495.00
6,399.00
Total Equity
9,403.00
8,736.00
8,574.00
7,495.00
6,399.00
Liabilities & Shareholders' Equity
9,531.00
8,920.00
8,800.00
7,732.00
6,708.00

About Tikcro Technologies

View Profile
Address
Kiryat Weizmann Science Park
Ness Ziona TA 7403630
Israel
Employees -
Website http://www.tikcro.com
Updated 07/08/2019
Tikcro Technologies Ltd. operates as a biopharmaceutical company. It pursues an early stage biotechnology project generating new antibodies for cancer treatment addressing immune modulation. This project is based on technology from the Weizmann Institute of Science in Israel.